Author Archive

Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator

• AUT00206 reduces the ketamine-induced BOLD response in a randomized placebo-controlled Phase Ib trial • Results are highly supportive of the potential for AUT00206 to treat psychiatric disorders such as…
Read More

WendyNews

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the…
Read More

WendyNews

About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.

Science

Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.

Pipeline

Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator, please take… https://t.co/A1hedx6tYy 
Apr 15 reply retweet favorite 6 days ago
Autifony Therapeutic  @AutifonyLtd
Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic appro… https://t.co/xOlDJ1kTe9 
Jan 18 reply retweet favorite 3 months ago
Autifony Therapeutic  @AutifonyLtd
Autifony is currently recruiting a Junior Medicinal Chemist, the position will be based in our lab in Stevenage, fo… https://t.co/PkP9TCxUcq 
Dec 04 reply retweet favorite 5 months ago

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image